How to Get AndroGel in Montana: Prescriptions, Telehealth, and Pharmacy Guide

What Is AndroGel and Why Montana Patients Need a Prescription Path

AndroGel is a hydroalcoholic testosterone gel applied to the shoulders, upper arms, or abdomen once daily to restore physiologic androgen levels in men with confirmed hypogonadism. The FDA approved testosterone gel 1% in 2000 and the higher-concentration 1.62% formulation in 2011, both manufactured by AbbVie. 1 Because testosterone is a Schedule III controlled substance under the Controlled Substances Act, every prescription requires a valid patient-prescriber relationship, documented diagnosis, and baseline laboratory data before the first dose is dispensed. 2

The Testosterone Trials (T-Trials), a coordinated set of seven double-blind placebo-controlled studies (N=790 men aged 65 or older with total testosterone below 275 ng/dL), showed that testosterone gel significantly improved sexual function, physical performance, and bone mineral density compared with placebo over 12 months. 3 That evidence base underpins the Endocrine Society's 2018 guideline, which specifies that testosterone therapy should be offered only to men with both consistently low testosterone levels and clinically relevant symptoms. 4

Montana's population is geographically dispersed across 147,000 square miles, meaning that many residents live hours from an endocrinologist or urologist. Telehealth prescribing and mail-order pharmacy options are therefore especially relevant for this state.

Montana Telehealth Laws and AndroGel Prescribing

Montana explicitly authorizes telehealth prescribing of controlled substances, including Schedule III androgens, provided the prescriber has established a valid patient-prescriber relationship before issuing the prescription. The Montana Telehealth Act (MCA 37-3-342) requires that relationship to involve a clinical evaluation sufficient to diagnose hypogonadism, which a comprehensive telehealth intake, laboratory review, and synchronous video visit can satisfy. 5

The prescriber must hold an active Montana license (or a valid interstate compact license recognized by Montana) and must document the clinical basis for the diagnosis in the medical record. A prescriber who prescribes AndroGel without reviewing at least two qualifying testosterone levels drawn on separate mornings risks a licensing violation under Montana Board of Medical Examiners rules. Short version: labs first, prescription second. No exceptions apply to Schedule III hormones.

Several national TRT telehealth platforms are licensed to operate in Montana, including HealthRX. A typical telehealth workflow looks like this:

1. Patient completes an online intake form describing symptoms (fatigue, reduced libido, erectile dysfunction, loss of muscle mass, mood changes).
2. The platform orders a lab panel at a draw site near the patient (LabCorp and Quest both operate collection sites in Billings, Missoula, Great Falls, Bozeman, and Butte).
3. A board-certified physician or licensed PA/NP reviews results during a video visit.
4. If criteria are met, a prescription is transmitted electronically to a mail-order or local pharmacy.

The American Urological Association's 2018 testosterone deficiency guideline states: "Clinicians should measure testosterone levels in the morning (before 10 AM) on at least two separate occasions before initiating testosterone therapy." 6 Following that protocol via telehealth is operationally straightforward for most Montana patients.

Lab Requirements Before an AndroGel Prescription in Montana

No responsible prescriber will initiate testosterone gel without a complete baseline panel. The minimum required labs align with both the Endocrine Society and the American Association of Clinical Endocrinology (AACE) guidelines. 4 7

Diagnostic labs (must be drawn fasting, before 10 AM):

• Total serum testosterone (two separate morning draws on different days)
• Luteinizing hormone (LH) and follicle-stimulating hormone (FSH) to differentiate primary from secondary hypogonadism
• Sex hormone-binding globulin (SHBG) to calculate free testosterone if total testosterone is borderline
• Prolactin (to exclude a pituitary adenoma if LH/FSH are low)

Safety baseline labs:

• Complete blood count (CBC) with hematocrit (testosterone stimulates erythropoiesis; baseline hematocrit above 50% is a relative contraindication)
• PSA (prostate-specific antigen) for men aged 40 and older, per FDA labeling
• Comprehensive metabolic panel (CMP)
• Estradiol (to assess aromatization baseline)

The FDA-approved labeling for AndroGel specifies that testosterone therapy is contraindicated in men with breast or prostate cancer, and the prescriber must document a normal digital rectal exam or PSA below 4 ng/mL before initiating therapy. 1 A total testosterone below 300 ng/dL on two separate morning draws, combined with at least three symptoms of hypogonadism, meets the diagnostic threshold most Montana telehealth providers apply, consistent with Endocrine Society guidance. 4

Monitoring labs at 3 months and 12 months after initiation should include total testosterone (drawn 2 to 4 hours after gel application for peak, or 8 to 10 hours after for a trough), hematocrit, PSA, and estradiol. Hematocrit above 54% requires dose reduction or temporary discontinuation under current safety guidance. 2

Who Can Prescribe AndroGel in Montana: MD, NP, and PA Scope

Montana is a full practice authority state for nurse practitioners. An NP with an active Montana license and a DEA Schedule III registration may independently prescribe AndroGel without physician oversight or a collaborative practice agreement. 8 Physician assistants in Montana practice under a supervising physician agreement but may prescribe Schedule III controlled substances within the scope of that agreement.

This broad prescriber pool benefits rural Montana patients significantly. A PA practicing at a frontier clinic in eastern Montana can legally prescribe AndroGel and manage TRT follow-up without routing every prescription through a physician. The key constraint is the DEA registration, not the professional degree. Any prescriber without an active DEA Schedule III registration cannot legally issue the prescription regardless of licensure tier.

The HealthRX clinical team uses a three-tier prescriber matching model for Montana patients: (1) patients with straightforward primary hypogonadism are matched to a licensed NP or PA for faster scheduling; (2) patients with elevated PSA, polycythemia risk, or secondary hypogonadism are routed to a board-certified physician; and (3) patients with pituitary findings or oncologic history are referred to an in-state endocrinologist or urologist before any prescription is issued.

AndroGel Dosing and Titration in Montana Prescriptions

The FDA-approved starting dose of AndroGel 1.62% is 40.5 mg (2 pump actuations) applied once daily to the upper arms or shoulders. The 1% formulation starts at 5 g once daily. Both concentrations are titrated based on serum testosterone drawn at the 4 to 6 week mark after steady-state is reached, typically at 4 weeks of consistent use. 1

Dose ranges per FDA labeling:

• AndroGel 1%: 5 g to 10 g per day (delivers 50 to 100 mg testosterone)
• AndroGel 1.62%: 20.25 mg to 81 mg per day (1 to 4 actuations)

Target serum testosterone is generally 400 to 700 ng/dL for most adult males, though the Endocrine Society notes that mid-normal range (450 to 600 ng/dL) is associated with the best symptomatic response in most men. 4 Levels above 700 ng/dL should prompt a dose reduction at the next monitoring visit.

Transfer precautions apply to gel formulations specifically: secondary exposure to women and children through skin contact has resulted in premature puberty in children and virilization in female partners. The FDA issued a Black Box Warning on all testosterone gel products for this reason. 2 Montana prescribers are required to counsel patients on covering the application site and washing hands thoroughly before contact with others.

AndroGel Pharmacies in Montana: Retail, Mail-Order, and 503A Compounding

Montana has no state-specific restriction on retail pharmacies dispensing testosterone gel. Any pharmacy holding a valid Montana Board of Pharmacy license and capable of handling Schedule III controlled substances may fill an AndroGel prescription. Major retail chains operating in Montana include Smith's (Billings), Albertsons Pharmacy, Walgreens, and independently owned pharmacies in smaller communities.

Mail-order options: Because Montana Medicaid does not cover AndroGel for male hypogonadism, most patients pay out-of-pocket or through private insurance. Cash prices for brand-name AndroGel 1.62% (30-day supply) range from $350 to $480 at Montana retail pharmacies as of early 2025. Manufacturer savings cards from AbbVie may reduce commercially insured copays to as low as $0 per month for eligible patients.

503A compounding pharmacies: Montana-licensed 503A compounding pharmacies may prepare testosterone gel in custom concentrations (commonly 2%, 5%, or 10%) when a prescriber documents a clinical reason that the commercially available product does not meet the patient's need, such as dose precision requirements or documented excipient sensitivity. The FDA's guidance on compounded drug products, updated in 2023, confirms that 503A pharmacies may compound testosterone preparations for individual patients on a prescription basis. 9 Compounded testosterone gel from a 503A pharmacy typically costs $30 to $80 per month for a 30-day supply, making it a meaningful cost option for uninsured Montana patients.

Compounded testosterone is not bioequivalent-tested against the brand product and is not FDA-approved, which means potency and absorption can vary by formulation. Prescribers should recheck serum testosterone at 6 weeks after any switch between brand and compounded gel to verify therapeutic levels are maintained. 10

Prior Authorization for AndroGel in Montana: Commercial Insurance

Montana Medicaid does not cover AndroGel for male hypogonadism, but many commercial plans do, subject to prior authorization (PA). The documentation packet a Montana insurer typically requires includes:

• Two fasting morning total testosterone values below 300 ng/dL (or below the plan's stated threshold, sometimes 280 ng/dL)
• Documentation that symptoms are consistent with hypogonadism (the prescriber's note must explicitly list the symptoms)
• Results of LH and FSH confirming primary or secondary etiology
• A statement that contraindications (prostate cancer, breast cancer, hematocrit above 50%) have been ruled out
• PSA result below 4 ng/mL for men aged 40 and older

Some Montana Blue Cross Blue Shield plans require a trial of lifestyle modification for 90 days before approving testosterone therapy in men with obesity-related secondary hypogonadism. If a PA is denied, the prescriber may appeal with additional clinical documentation or prescribe a compounded 503A alternative that the insurer cannot block. Montana law under MCA 33-22-526 prohibits insurers from requiring step therapy through a non-covered alternative before approving a covered medically necessary therapy when the prescriber certifies step therapy is clinically inappropriate. 11

A 2022 analysis published in JAMA Internal Medicine found that prior authorization delays for testosterone therapy averaged 8.3 days across commercial insurers, with 22% of initial requests denied. 12 Patients who preemptively submit a complete lab packet at the time of the PA request reduce that denial rate substantially.

Transferring an Out-of-State AndroGel Prescription to Montana

Montana Pharmacy Act (MCA 37-7-101) permits transfer of a Schedule III controlled substance prescription between licensed pharmacies across state lines, provided the receiving pharmacy verifies the prescription's validity with the originating pharmacy and both hold active DEA registrations. 13 A Schedule III prescription for testosterone may be transferred one time only under federal law (21 CFR 1306.25), unless the pharmacies share a real-time electronic database, in which case unlimited transfers are permitted.

Patients relocating to Montana who have an active AndroGel prescription from another state should:

1. Call the receiving Montana pharmacy and provide the originating pharmacy's name, address, and phone number.
2. Ask the Montana pharmacist to initiate the transfer (the receiving pharmacist contacts the dispensing pharmacist directly).
3. Confirm the prescriber holds a valid license recognizable in Montana. If not, a new Montana-licensed prescriber must co-sign or reissue the prescription before the pharmacy can dispense.

Telehealth patients often find it easier to initiate a new prescription through a Montana-licensed provider than to manage a cross-state transfer. A fresh telehealth evaluation takes 3 to 7 business days from lab draw to prescription transmission, which is faster than resolving transfer complications for prescriptions written by out-of-state providers who lack Montana licensure.

How Long Until You Receive AndroGel in Montana

The total time from first contact with a prescriber to receiving AndroGel at your door depends on the pathway chosen.

Telehealth plus mail-order pathway:

• Lab order placed and patient draws blood: day 0 to day 2
• Lab results returned to prescriber: day 2 to day 3 (most Quest and LabCorp panels result in 24 to 48 hours)
• Video visit with prescriber: day 3 to day 5
• Prescription transmitted to mail-order pharmacy: same day as visit
• Pharmacy processing and shipping: 2 to 5 business days
• Total: 5 to 10 business days from intake to first dose

Local retail pharmacy pathway:

• Same lab and visit timeline as above
• Prescription sent electronically to local pharmacy
• Dispensing same day or next day if inventory is available
• Total: 4 to 7 business days

Rural Montana patients in ZIP codes without a nearby LabCorp or Quest draw site can use mobile phlebotomy services or ship their own blood draw kit; processing adds 1 to 2 days in those cases. Home blood draw kits compatible with testosterone panels are available through several CLIA-certified labs that operate in Montana.

Cost of AndroGel in Montana Without Insurance

Brand-name AndroGel 1.62%, 30-day supply (75 g pump bottle, 60 actuations): $350 to $480 cash price at Montana retail pharmacies as of Q1 2025. GoodRx coupons reduce the price to approximately $250 to $320 at participating pharmacies. The AbbVie AndroGel savings card brings the copay to $0 per month for commercially insured patients and to approximately $120 per month for cash-pay patients who qualify.

Compounded testosterone gel (2% concentration, 30-day supply from a Montana 503A pharmacy): $35 to $80 per month. This represents the most cost-effective option for uninsured patients, provided the prescriber documents a valid clinical reason for compounding rather than dispensing the brand product. 9

Generic testosterone gel (1%) is available from manufacturers including Perrigo and Teva at prices ranging from $60 to $130 per month at Montana retail and mail-order pharmacies, offering a middle-tier option between compounded and brand-name products.

Safety Monitoring After Starting AndroGel in Montana

The FDA's 2015 safety communication on testosterone products requires that prescribers inform patients of the cardiovascular risk signals identified in observational data, though the T-Trials (N=790) showed no statistically significant increase in major adverse cardiovascular events over 12 months. 3 2 A 2023 randomized trial (TRAVERSE, N=5,204 men with hypogonadism and elevated cardiovascular risk) found that testosterone replacement did not increase the rate of major adverse cardiovascular events (MACE) compared with placebo, with a hazard ratio of 0.96 (95% CI 0.78 to 1.17). 14

Montana telehealth prescribers should document the following monitoring schedule in the care plan:

• Week 6: serum testosterone (2 to 4 hours post-application), hematocrit, estradiol
• Month 3: full panel including PSA, CBC, CMP, testosterone
• Month 6: hematocrit and PSA at minimum
• Month 12: full panel, repeat every 12 months thereafter if stable

Hematocrit above 54% requires hold and dose reduction. PSA rise of more than 1.4 ng/mL above baseline in any 12-month period warrants urology referral before continuing therapy, per Endocrine Society guidance. 4